Donald Hayden

Donald Hayden General Information

Description

Mr. Donald Hayden is an angel investor. He serves as Chief Executive Officer & Chairman at WindMIL Therapeutics. He serves as a Senior Advisor at Prospect Venture Partners. He served as the Chairman at Nora Therapeutics. He brings to Prospect the experiences and perspective resulting from a highly successful 25-year career with Bristol-Myers Squibb Company as well as the insights gained from key roles at a number of smaller, more entrepreneurial pharmaceutical and biotech companies over the past 5 years. At Bristol-Myers Squibb, Mr. Hayden served as President of Global Pharmaceuticals; Executive Vice President and President, of Americas, overseeing two major pharmaceutical units and two healthcare businesses; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President for Worldwide Franchise Management and Business Development. Since leaving Bristol-Myers Squibb in early 2006, Mr. Hayden has served as Chairman of Gloucester Pharmaceuticals, Vitae Pharmaceuticals, Insmed, and Azelon Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Nora Therapeutics. Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University. He also serves as a Board member at Satori Pharmaceuticals.